These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 23169228)

  • 1. [Candidate patient for treatment with continuous apomorphine infusion].
    Martí MJ; Kulisevsky J
    Rev Neurol; 2012; 55 Suppl 1():S15-9. PubMed ID: 23169228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Candidate patient for subcutaneous apomorphine injection].
    Chacón JR; Mata M
    Rev Neurol; 2012; 55 Suppl 1():S7-9. PubMed ID: 23169232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of apomorphine infusion adverse effects: subcutaneous nodules and neuropsychiatric complications].
    Giménez de Béjar V; Carballo-Cordero M
    Rev Neurol; 2012; 55 Suppl 1():S25-9. PubMed ID: 23169230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Subcutaneous continuous apomorphine infusion: treatment initiation and follow up].
    Grandas FJ; Sesar-Ignacio Á
    Rev Neurol; 2012; 55 Suppl 1():S21-4. PubMed ID: 23169229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Continuous subcutaneous infusion of apomorphine in Parkinson's disease: retrospective analysis of a series of 81 patients].
    Rambour M; Moreau C; Salleron J; Devos D; Kreisler A; Mutez E; Simonin C; Annic A; Dujardin K; Destée A; Defebvre L
    Rev Neurol (Paris); 2014 Mar; 170(3):205-15. PubMed ID: 24594365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
    Chen JJ; Obering C
    Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advanced Parkinson's disease: clinical characteristics and treatment. Part II.
    Kulisevsky J; Luquin MR; Arbelo JM; Burguera JA; Carrillo F; Castro A; Chacón J; García-Ruiz PJ; Lezcano E; Mir P; Martinez-Castrillo JC; Martínez-Torres I; Puente V; Sesar A; Valldeoriola-Serra F; Yañez R
    Neurologia; 2013; 28(9):558-83. PubMed ID: 23880230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous subcutaneous apomorphine infusion in Parkinson's disease patients with cognitive dysfunction: A retrospective long-term follow-up study.
    Borgemeester RWK; van Laar T
    Parkinsonism Relat Disord; 2017 Dec; 45():33-38. PubMed ID: 29032012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Literature review: intermittent subcutaneous apomorphine therapy in Parkinson's disease.
    Factor SA
    Neurology; 2004 Mar; 62(6 Suppl 4):S12-7. PubMed ID: 15037666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apomorphine therapy in Parkinson's disease: a review.
    Haq IU; Lewitt PA; Fernandez HH
    Expert Opin Pharmacother; 2007 Nov; 8(16):2799-809. PubMed ID: 17956200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apomorphine: North American clinical experience.
    Stacy M
    Neurology; 2004 Mar; 62(6 Suppl 4):S18-21. PubMed ID: 15037667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of apomorphine in Parkinson's disease.
    Stocchi F
    Neurol Sci; 2008 Dec; 29 Suppl 5():S383-6. PubMed ID: 19381769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
    Deleu D; Hanssens Y; Northway MG
    Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease.
    Colzi A; Turner K; Lees AJ
    J Neurol Neurosurg Psychiatry; 1998 May; 64(5):573-6. PubMed ID: 9598668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Other formulations and future considerations for apomorphine for subcutaneous injection therapy.
    Koller W; Stacy M
    Neurology; 2004 Mar; 62(6 Suppl 4):S22-6. PubMed ID: 15037668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up.
    Kanovský P; Kubová D; Bareš M; Hortová H; Streitová H; Rektor I; Znojil V
    Mov Disord; 2002 Jan; 17(1):188-91. PubMed ID: 11835461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of increasing doses of apomorphine during stereotaxic neurosurgery in Parkinson's disease: clinical score and internal globus pallidus activity. Short communication.
    Stefani A; Stanzione P; Bassi A; Mazzone P; Vangelista T; Bernardi G
    J Neural Transm (Vienna); 1997; 104(8-9):895-904. PubMed ID: 9451721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An evaluation of subcutaneous apomorphine for the treatment of Parkinson's disease.
    Müller T
    Expert Opin Pharmacother; 2020 Oct; 21(14):1659-1665. PubMed ID: 32640853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apomorphine for the acute treatment of "off" episodes in Parkinson's disease.
    Stacy M; Silver D
    Parkinsonism Relat Disord; 2008; 14(2):85-92. PubMed ID: 18083605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuous apomorphine infusion (CAI) and neuropsychiatric disorders in patients with advanced Parkinson's disease: a follow-up of two years.
    Morgante L; Basile G; Epifanio A; Spina E; Antonini A; Stocchi F; Di Rosa E; Martino G; Marconi R; La Spina P; Nicita-Mauro V; Di Rosa AE
    Arch Gerontol Geriatr Suppl; 2004; (9):291-6. PubMed ID: 15207426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.